Skip to main contentSkip to navigation
Sirius Investors

BioNexus Gene Lab Corp. (BGLC) Investment Research Dashboard

About BioNexus Gene Lab Corp. (BGLC) stock analysis

Get live BGLC stock price $1.51, comprehensive BioNexus Gene Lab Corp. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time BGLC stock data and investment insights.

1.51
1.95%Today
Market Cap
3.04M
Volume
4.75K
52W High
8.98
52W Low
1.07

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical ...

Company Information

CEO
Su-Leng Tan
Sector
Industrials
Industry
Industrial - Distribution
Employees
19

Contact Information

Address
Tower B, Vertical Business Suite
Country
MY

Investment Analysis & Business Insights

Industrials
Industrial - Distribution

Investment Highlights

Strong presence in the Industrials sector with established market position

Higher growth potential with elevated volatility (Beta: 2.21)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for BioNexus Gene Lab Corp. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Industrials may affect company performance
  • Past performance does not guarantee future results for BioNexus Gene Lab Corp.
  • Investors should consider how BioNexus Gene Lab Corp. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

3.04M

P/E Ratio (TTM)

-1.01

Beta

2.21

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Industrials Sector

The Industrials sector includes companies that manufacture machinery, provide transportation services, and offer industrial products and services.

Industrials (1D)

10/100

Overall
-0.5%
NYSE
-0.3%
NASDAQ
-0.8%
Sector1D1W1MP/EScore
Financial Services+0.3%+0.9%+3.0%19.0
85/100⭐⭐⭐⭐⭐
Healthcare+0.2%+1.0%+4.1%23.5
84/100⭐⭐⭐⭐⭐
Real Estate+1.8%+2.1%-0.3%29.7
72/100⭐⭐⭐⭐⭐
Communication Services+0.7%-2.5%+2.8%21.8
62/100⭐⭐⭐⭐
Basic Materials+0.9%+0.4%-1.3%24.9
55/100⭐⭐⭐⭐
Consumer Defensive+0.8%-0.0%-0.9%28.7
53/100⭐⭐⭐
Utilities-0.7%+2.0%-1.3%25.2
52/100⭐⭐⭐
Energy-0.2%+0.4%-2.4%19.6
49/100⭐⭐⭐
Consumer Cyclical+0.3%-3.1%-2.8%43.3
14/100
Technology-1.6%-0.3%-3.1%42.2
14/100
Industrials-0.5%-1.3%-8.9%30.4
10/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-26.